Standard Biotools (LAB) Cash from Investing Activities Growth (3y) (2013 - 2026)
Standard Biotools (LAB) Cash from Investing Activities Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.67 Bn | 194.07 Bn | 7.27 Bn | 17.83% |
| 2 | Stryker | 129.56 Bn | 126.09 Bn | 4.50 Bn | -6.23% |
| 3 | Medtronic | 119.87 Bn | 110.65 Bn | 6.41 Bn | -24.52% |
| 4 | Boston Scientific | 73.80 Bn | 73.27 Bn | 3.85 Bn | -32.54% |
| 5 | Edwards Lifesciences | 52.66 Bn | 48.41 Bn | 1.35 Bn | -68.12% |
| 6 | Dexcom | 34.56 Bn | 32.61 Bn | 830.00 Mn | 37.39% |
| 7 | GE HealthCare Technologies | 34.16 Bn | 32.05 Bn | 2.18 Bn | -11.04% |
| 8 | Koninklijke Philips | 26.44 Bn | 23.12 Bn | 4.55 Bn | 19.58% |
| 9 | Steris | 23.23 Bn | 22.75 Bn | 684.20 Mn | -17.67% |
| 10 | Standard Biotools | 258.10 Mn | -218.62 Mn | 10.54 Mn | -28.92% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -28.92% |
| Mar 31, 2026 | 64.21% |
| Dec 31, 2025 | -30.05% |
| Sep 30, 2025 | -37.90% |
| Jun 30, 2025 | 30.04% |
| Mar 31, 2025 | 166.13% |
| Sep 30, 2024 | -41.93% |
| Jun 30, 2024 | 95.97% |
| Mar 31, 2024 | 305.37% |
| Dec 31, 2023 | -151.76% |
| Sep 30, 2023 | -79.45% |
| Jun 30, 2023 | 58.24% |
| Mar 31, 2023 | 35.20% |
| Dec 31, 2022 | 321.79% |
| Sep 30, 2022 | 17.91% |
| Jun 30, 2022 | -57.26% |
| Mar 31, 2022 | 55.36% |
| Sep 30, 2021 | -149.16% |
| Jun 30, 2021 | -60.91% |
| Mar 31, 2021 | -165.52% |